정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 828 | Recruiting | PREvent Viral Exposure aNd Transmission Study: a SARS-CoV-2 PEP Study (PREVENT) | Respiratory Tract Diseases | Drug: RESP301, a Nitric Oxide generating solution | Phase 3 | Thirty Respiratory Limited | INDUSTRY | 600 | All | 18 Years | Imperial College Healthcare NHS Trust, London, United Kingdom |
| 827 | Recruiting | Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. | COVID-19 | Drug: Aspirin 75mg Drug: Clopidogrel 75mg Drug: Rivaroxaban 2.5 MG Drug: Atorvastatin 40mg Drug: Omeprazole 20mg |
Not Applicable | Imperial College London | OTHER | 3170 | All | 18 Years ~ 85 Years | Charing Cross Hospital, London, United Kingdom |
| 826 | Terminated | Preventing COVID-19 Complications With Low- and High-dose Anticoagulation | Sars-CoV2 | Drug: Enoxaparin | Phase 3 | University Hospital, Geneva | OTHER | 160 | All | 18 Years | Geneva University Hospitals, Geneva, Switzerland Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland Ospedale Regionale di Locarno, Locarno, Switzerland Hopital du Valais, Sion, Switzerland |
| 825 | Withdrawn | Preventing COVID-19 in Healthcare Workers With HCQ: A RCT | Covid-19 | Drug: Hydroxychloroquine Other: Vitamin C |
Phase 2 | Stony Brook University | OTHER | 0 | All | 18 Years | |
| 824 | Not yet recruiting | Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 | Severe Acute Respiratory Syndrome | Drug: RESP301 | Phase 3 | University of Birmingham, Christian Medical College and Hospital, Ludhiana, India, Tamale Teaching Hospital, Ghana., University of Lagos, Nigeria, Kigali University Teaching Hospital, Hospital Espanol Veracruz, Universite d'Abomey-Calavi, University of Witwatersrand, South Africa, University of Edinburgh, Istituto Clinico Humanitas, University of Cape Town | OTHER | 6400 | All | 18 Years | |
| 823 | Recruiting | Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia | Covid-19 | Drug: Ivermectin Drug: ASP Drug: Placebo |
Phase 3 | London School of Hygiene and Tropical Medicine | OTHER | 1200 | All | 5 Years | Mrcg@Lshtm, Fajara, Gambia |
| 822 | Active, not recruiting | Prevention and Treatment of Patient Before, During, and After Covid-19 Infection | Covid19 | Drug: AntiCov-220 | Phase 2 | Nguyen Thi Trieu, MD | INDIV | 82 | All | 16 Years ~ 82 Years | Saigon Biopharma Company Limited, Ho Chi Minh City, Vietnam |